(Q84622432)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

2

Christian Blank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

6

John Haanen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Axel Bex

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Wim Meinhardt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Harm van Tinteren

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Simon Horenblas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

29 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

832-837

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Sequential therapy in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.034

10.1016/J.UROLOGY.2011.05.034

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21802123%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference